On this page
Back to topParabilis Medicines PBLS
Parabilis Medicines listed on Nasdaq on 10 Jun 2026 and is not in the S&P 500. It is worth $3.5 billion. Its price history starts on 12 Jun 2026. 11 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 5 other officers are on file. At 30 Jun 2026, Ra Capital Management was its largest institutional holder, with 23.4% of the company.
- CEO
- Mathai Mammen
- Listed
- 10 Jun 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Cambridge, MA
- Market cap
- $3.5B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Financial history
Twelve months to 30 Sep 2026, from Parabilis Medicines's quarterly filings.
Quarters since Jun 2026
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Jun 2026 to Sep 2026
Not reported for enough quarters.
Not reported for enough quarters.
Not reported for enough quarters.
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $2M | $-44M |
| Jun 2026 | $148,000 | $-52M |
Parabilis Medicines's market cap since June 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $3.6B |
Download Parabilis Medicines's data as JSON, with the weekly market caps in billions of dollars from 12 Jun 2026.
Board and leadership
Board and officers
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (11) | |
| Mathai MammenPresident & CEO | |
| Alexis BorisyDirector | |
| Edward M. FitzgeraldDirector | |
| Richard KlausnerDirector | |
| Peter KolchinskyDirector | |
| Alan SebulskyDirector | |
| Rajeev M. ShahDirector | |
| Jake SimsonDirector | |
| Craig TendlerDirector | |
| Barbara WeberDirector | |
| Krishna YeshwantDirector | |
| Officers (5) | |
| Thomas Rodolpho KotarakosChief Financial OfficerLast filed 9 Jun 2026 | |
| Mohammed Fawzi BenzaghouChief Medical OfficerLast filed 9 Jun 2026 | |
| Helen Huei-in HoChief Business and Strategy OfficerLast filed 9 Jun 2026 | |
| Teresa JurgensenGeneral CounselLast filed 9 Jun 2026 | |
| Rohin MhatreChief Technical Operations OfficerLast filed 9 Jun 2026 | |
Owners and trading
Largest institutional holders
Each fund group's share of Parabilis Medicines. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $431 million in 7 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 22 Jul 2026Buy | Peter KolchinskyDirector | $1.4M |
| 21 Jul 2026Buy | Peter KolchinskyDirector | $1.9M |
| 20 Jul 2026Buy | Peter KolchinskyDirector | $3.6M |
| 15 Jun 2026Buy | Alan SebulskyDirector | $240K |
| 12 Jun 2026Buy | Alan SebulskyDirector | $233K |
| 11 Jun 2026Buy | Peter KolchinskyDirector | $424M |
| 11 Jun 2026Buy | Alan SebulskyDirector | $250K |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 departure and 1 appointment of directors and officers in the last two years.
Events, newest first
- 28 Aug 2026 Fawzi Benzaghou leftChief Medical Officer, effective 30 Sep 2026
- 22 Aug 2026 Craig Tendler appointedDirector
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.